+1-888-308-5802     
Industry Categories News Contact Us

Iterum to conduct trials for oral Sulopenem in uncomplicated UTIs

Author : Ojaswita Kutepatil | Published Date : 2018-08-11 

Pharmaceutical giant Iterum Therapeutics plc, which develops medications for infections caused by multi-drug resistance pathogens, has recently announced its clinical trial for Sulopenem. Sources state that this would mark the first phase of its Phase 3 clinical trials.

For the uninitiated, Sulopenem works well during in-vitro activity to fight organisms commonly concerned with urinary tract and intra-abdominal infections. According to reliable sources, in the trial known as Sulopenem for Resistant Enterobacteriaceae (Sure) 1, the oral sulopenem will be compared to oral ciprofloxacin in women down with uncomplicated urinary tract infections (uUTI).

Sulopenem is Iterum’s lead compound and new antibiotic meant to cure gram-negative and multi-drug resistant infections. 

As per a news release by Iterum, patients infected with quinolone resistant pathogen may need secondary antibiotic prescription or hospitalization, if quinolone is prescribed for uncomplicated UTI. Among U. S patients, resistance to fluoroquinolone has been observed in over 20% of isolates from urinary tract caused primarily by resistance to E. coli and P.mirabilis.

The growth of UTIs with multi-drug resistance is disturbing and current drugs fail in treatment, claimed Iterum’s M.D. and Chief Scientific Officer, Michael Dunne. Resistance to fluoroquinolones is rising and healthcare professionals urgently need new oral options to treat infections such as UTIs, he further added.

FDA has warned about the usage of fluoroquinolones for uUTI patients who can be prescribed other drugs as well, as it poses more risks than benefits, stated Dunne.

Approximately 1,364 patients are expected to enroll for the study conducted under an agreement of Special Protocol Assessment (SPA) from the FDA. The trial process will be carried out with patients receiving either oral sulopenem twice for five days or oral ciprofloxacin twice for three days, the ideal uUTI dosage.

Incidentally, Iterum is in talks for initiating two additional Phase 3 clinical trials that will examine the use of oral and intravenous sulopenem in complicated UTIs and complicated intra abominable infections, reported sources familiar with the trials.

About Author

Ojaswita Kutepatil

Ojaswita Kutepatil

Ojaswita Kutepatil, a mechanical engineer by qualification, worked as a BDE and Technical Engineer before switching her profession to content writing. Currently, she works at AlgosOnline. as an Content writer, where she pens down write-ups pertaining to the market research industry. Crafting, reading, and music are some of her other areas of interest.

She can be contacted at- [email protected] | https://twitter.com/ojaswita_k

Related News

NextDC invests $2.25 billion to build data centers in Australia

Published Date: 2018-09-02         Author: Ojaswita Kutepatil

Leading data center operator NextDC has declared plans to spend $2.25 billion on sites in Melbourne, Perth, and Sydney. The new sites will be developed into data centers for the likes of drones, nanotechnology and precision medicine. The purchase of the new north shore site has been funded by a r... Read More

Facebook pledges to run data centers on 100% renewable energy by 2020

Published Date: 2018-08-30         Author: Ojaswita Kutepatil

As a part of its pledge to combat climate change, Facebook has recently announced that it will be reducing its greenhouse gas emissions by 75% and will power its global operations with 100% renewable energy by 2020. According to sources familiar with the matter, the social-media behemoth has sign... Read More

Snam signs MOU with China’s SGID, focuses on low-emission economy

Published Date: 2018-08-29         Author: Ojaswita Kutepatil

In a bid to explore better opportunities of future cooperation in infrastructure & new technologies for a low-emission economy, the Italian transmission system operator (TSO) Snam has inked a Memorandum of Understanding (MoU) with China’s State Grid International Development Company (SGID)... Read More

© 2018 Fractovia. All Rights Reserved